New Phorum to accelerate delivery of cell and gene therapy revolution

New Phorum to accelerate delivery of cell and gene therapy revolution

Cell and gene therapies are the hot topic within the healthcare industry. Stories about developments in the field appear across major news networks around the world on an almost daily basis and the growing need for collaboration between companies to tackle common challenges is becoming ever more apparent.

BioPhorum is therefore delighted to announce the launch of the new Cell and Gene Therapy Phorum where companies can work together to address some of the key challenges that bio-pharmaceutical companies are facing in this area.

 

 

“There are several national initiatives emerging in cell and gene therapy but there is nothing else like this Phorum available at the moment,” explains Christelle Simpson-Platre, Phorum Lead. “Converting the vast potential of these therapies into a robust, reproducible, safe, efficacious, and cost effective reality for the treatment of all patients is a very exciting challenge. When you put the expertise and the collective resolution of the companies leading the way in Cell and Gene therapy together with BioPhorum’s experience and proven track record for industry collaboration there is a really unique opportunity to accelerate delivery of these therapies here.”

The Cell and Gene Therapy Phorum met for the first time at a face-to-face meeting in April 2018 in Boston, USA to set out their goals for the future to lead the way on industry alignment. Cell and gene therapies are disruptive technologies and when coupled with their success present significant challenges in aligning efforts across bio-pharmaceutical companies, biotechs and academia. These challenges extend into delivery paradigms, regulatory landscape and throughout the supply chain as the industry seeks to rapidly develop and deliver life-changing therapies. BioPhorum has a track record of solving complex common challenges at an industry level within the bioprocessing field and is excited to be able to support this field on its journey at an early stage.

The new Phorum is bringing industry leaders together to tackle six key, pre-competition common interest challenges which they have identified as: high level analytics, regulatory strategy, commercialization, validation, raw material sourcing and supply, and environmental health and safety. Addressing these challenges now will avoid multiple industry solutions.

These areas will also form the basis for six workstreams within the Phorum and the team are busy developing charters for each workstream which fit together into a co-ordinated programme. At the same time, BioPhorum is busy securing sponsor commitment from participating companies.

The business of cell and gene therapy is as diverse as the patients which it serves and for that there is no one size fits all solution. It was described by one participant at the meeting as the “wild west” of the industry that could benefit from the systematic approach that BioPhorum is known for facilitating. It is this focus on tangible results that BioPhorum will deliver while ensuring that the creativity of those involved is not overwhelmed by stringent structures. It is because of the visionaries within this arena that the creativity has been able to flourish. Creating a collaboration that works around this and ensuring robust participation from all members will be the driving force behind achieving the Phorum’s goals.

Member companies anticipate that this new Phorum will provide a full awareness of the market place, an understanding of new innovations within the field, an ability to share capabilities and offerings, technological advances and benchmarking across the industry.

The team will meet again in the fourth quarter to progress the Phorum’s goals.

Please contact Christelle Simpson-Platre on christelle@biophorum.com if you would like to learn more, or would like to become involved.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Industry bioassay approach helps to shape the future

In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Proactive prioritization: a new tool for assessing raw material risk

The Raw Material Risk Management workstream has launched a new, raw material risk assessment tool aimed at helping industry identify and prioritize around the challenging[...]

Read More
How well can you handle SUS changes?  Take our surveys and see

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Companies poised to follow ARMM recommendations

The Advanced and Rapid Microbial Methods (ARMM) team set out a clear case for modernizing Environmental Monitoring (EM) in grade A settings: in summary bio-fluorescent[...]

Read More
How to achieve the ‘Goldilocks’ amount of environmental monitoring

Regulators require a risk-based approach to environmental monitoring (EM)… but they give no clear definition of what “risk-based” actually means. The aim of the Environmental[...]

Read More
Logistics collaboration hub: An opportunity for significant time and cost savings

Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
BioPhorum and Rx-360 pilot a joint audit model for single-use systems

BioPhorum and Rx-360 have agreed a pilot to validate the use of the Joint Audit Model in the single-use systems supply chain.

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Regulatory compliance: what lessons can be learned?

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More